Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
F F Federico Ferranti
Observed name:
Federico Ferranti
Institution:
Sapienza University of Rome
Observed institution:
Sapienza University of Rome
ORCID:
0009-0002-7113-7656
Observed ORCID:
0009-0002-7113-7656
OpenAlex ID:
A5139513095
Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology
2025
·
Paolo Severino
, Andrea D’Amato
, et al.
·
Cardiovascular Drugs and Therapy
·
6
PDF
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF
2025
·
Andrea D’Amato
, Silvia Prosperi
, et al.
·
American Journal of Cardiovascular Drugs
·
3
PDF
HLM Staging and Treatment Benefit of SGLT2i Across Heart Failure Severity
2026
·
Andrea D’Amato
, Federico Ferranti
, et al.
·
Journal of Cardiovascular Development and Disease
PDF
From COVID-19 to influenza A - recurrent viral myocarditis and successful immunosuppressive therapy: A case report and review of literature
2026
·
Lucia Ilaria Birtolo
, Federico Ferranti
, et al.
·
World Journal of Cardiology
A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF)
2026
·
A D'amato
, C S Camilla Segato
, et al.
·
European Journal of Heart Failure
Simultaneous Introduction of Heart Failure Therapy During Hospitalization: Results on 12- Months Follow up
2025
·
Andrea D’Amato
, Paolo Severino
, et al.
·
Journal of the American College of Cardiology
PDF
Show more works
View as search
Works count:
6
Citation count:
9
H-index:
2
I10-index:
Year
Topic
Type